Clinical Trials Sponsored by Innovate UK

Total 1607 results

Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL

PCNSL | Secondary Central Nervous System Lymphoma

China
French Innovative Leukemia Organisation
Novartis Pharmaceuticals

Active, not recruiting

Study Impact on Outcome of Eltrombopag in Elderly Patients With Acute Myeloid Leukemia Receiving Induction Chemotherapy (EPAG2015)

Acute Myeloid Leukemia

France
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Subjects

Healthy Subjects

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study to Evaluate ICP-022 in Patients With CLL/ SLL

CLL/SLL

China
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

Study of ICP-105 in Solid Tumors Patients

Solid Tumor

China
French Innovative Leukemia Organisation
Novartis Pharmaceuticals

Terminated

The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line

Essential Thrombocythemia

France
Foundation for Innovative New Diagnostics, Switzerland

Unknown

Performance Evaluation of Malaria Plus RDTs

Malaria
University of Edinburgh
Innovative Medicines Initiative

Terminated

European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study (LCS) (EPAD-LCS)

Alzheimer's Dementia

United Kingdom, Belgium, France, Greece, Italy, Netherlands, Spain, Sweden, Switzerland
Novartis Pharmaceuticals
Innovative Medicines Initiative

Withdrawn

Study to Evaluate the Impact of the "PROactive Telecoaching Program" on Physical Activity in Patients With COPD. (PROactive)

COPD
NHS Greater Clyde and Glasgow
INNOVATEUK

Not yet recruiting

The PARS Study: Paediatric Advanced Respiratory Service Study - An Observational Diagnostic Feasibility Study (PARS)

Sleep Disordered Breathing | Apnea of Prematurity | Respiratory Rate

United Kingdom
Foundation for Innovative New Diagnostics, Switzerland

Recruiting

BGM and HbA1c POC Device Evaluation

Diabetes

Nigeria, Cambodia, Colombia
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia

Chronic Primary Immune Thrombocytopenia (ITP)

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma

Relapsed and/or Refractory Multiple Myeloma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject

Hepatic Impairment

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma (ICC)

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations

Advanced Solid Tumor

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study of ICP-192 in Patients With Advanced Solid Tumors

Advanced Solid Tumors | Cholangiocarcinoma | Urothelial Carcinoma

Australia, United States
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Clinical Study of ICP-192 in Solid Tumors Patients

Solid Tumor

China
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Study of ICP-022 in Patients With R/R DLBCL (DLBCL)

Diffuse Large B Cell Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia

Waldenstrom's Macroglobulinemia Recurrent | Waldenstrom's Macroglobulinemia Refractory

China
Foundation for Innovative New Diagnostics, Switzerland

Completed

COVID-19 Novel Molecular Point of Care Diagnostics Evaluation

COVID-19 Respiratory Infection

Switzerland, Uganda, United Kingdom
Foundation for Innovative New Diagnostics, Switzerland

Completed

Clinical Evaluation of tNGS for Diagnosis of DR-TB (Seq&Treat)

Tuberculosis, Multidrug-Resistant

Georgia, India, South Africa
French Innovative Leukemia Organisation
Janssen, LP

Active, not recruiting

Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction (IDA53)

Relapsed or Refractory Chronic Lymphocytic Leukemia

France
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Hematoma

China
Center for Innovative Public Health Research

Unknown

Girl2Girl: A Web-based Trial (G2G)

Pregnancy Prevention

United States
Foundation for Innovative New Diagnostics, Switzerland

Completed

Actionable Results: Bloodstream Infection Molecular Assay Evaluation

Bloodstream Infection

Botswana
Foundation for Innovative New Diagnostics, Switzerland

Completed

Prospective Assessment of TBDx Feasibility

Pulmonary Tuberculosis

Vietnam, Peru
French Innovative Leukemia Organisation
Novartis Pharmaceuticals

Completed

Phase I Study in RAD 001 Patients With Relapse AML

AML

France
Imperial College Healthcare NHS Trust
Chugai Pharma UK Limited

Recruiting

Comparing the Current Hydration Regimen for the ABC02 Chemotherapy Regimen Versus a Shorter Hydration

Gallbladder Cancer

United Kingdom
University Hospitals of North Midlands NHS Trust
Diabetes UK

Recruiting

Is Fat in the Liver a Marker of Post-Pregnancy Glycaemic Deterioration in Women With Gestational Diabetes? (FLiP-GD2)

Gestational Diabetes

United Kingdom
Institute of Cancer Research, United Kingdom
Prostate Cancer UK

Recruiting

Molecular Stratification Profiling Protocol in Metastatic Castration Resistant Prostate Cancer (mCRPC) - MAESTRO (MAESTRO)

Castration-resistant Prostate Cancer | Metastatic Prostate Cancer

United Kingdom
Reckitt Benckiser Healthcare (UK) Limited
Premier Research Group plc

Completed

Efficacy of 300 mg Ibuprofen Prolonged-Release Tablets for the Treatment of Pain After Surgical Removal of Impacted Third Molars

Pain

United States
University College, London
Roche Pharma AG; Cancer Research UK

Completed

Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma

Lymphoma

New Zealand, United Kingdom, Australia
University College, London
Medical Research Council; Alcohol Research UK

Completed

Alcohol Consumption and Arterial Stiffness: A Longitudinal Study of Pulse Wave Velocity in the Whitehall II Cohort

Aortic Stiffness

United Kingdom
The Christie NHS Foundation Trust
AstraZeneca; Cancer Research UK

Terminated

Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial (DREAMtherapy)

Rectal Cancer

United Kingdom
University of Oxford
Public Health England; Cancer Research UK

Active, not recruiting

Extending the National Health Service (NHS) Breast Screening Age Range (AgeX)

Breast Cancer Mortality

United Kingdom
Reckitt Benckiser Healthcare (UK) Limited
Novotech (Australia) Pty Limited

Completed

A Clinical Investigation to Assess the Performance of a Polyurethane Condom Versus a Latex Condom in Healthy Monogamous Couples

Control of Pregnancy | Prevention of Sexually Transmitted Infections

Thailand
University of Nottingham
Swansea University; Multiple Sclerosis Society UK

Completed

The PrEliMS Feasibility Trial (PrEliMS)

Multiple Sclerosis

United Kingdom
Institute of Cancer Research, United Kingdom
Cancer Research UK

Completed

Apparent Diffusion Coefficient as a Prognostic Biomarker in Cervical Cancer

Cancer

United Kingdom
University College, London
Hoffmann-La Roche; Cancer Research UK

Completed

Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery (BACCHUS)

Rectal Cancer

United Kingdom
University of Cambridge
Medical Research Council; Cancer Research UK

Active, not recruiting

The European Prospective Investigation Into Cancer in Norfolk Prospective Population Study (EPIC-Norfolk)

Cardiovascular Diseases | Neoplasms | Death
Institute of Cancer Research, United Kingdom
Cancer Research UK

Unknown

Radiation Therapy in Women With Low Risk Early-Stage Breast Cancer Who Have Undergone Breast Conservation Surgery (IMPORT)

Breast Cancer

United Kingdom
Institute of Cancer Research, United Kingdom
Cancer Research UK

Unknown

A Study of Prostate and pelvIs Versus prOsTate Alone Treatment for Locally Advanced Prostate Cancer (PIVOTAL)

Prostate Cancer

United Kingdom
Cambridge University Hospitals NHS Foundation Trust
Arthritis Research UK

Unknown

Acquired Immunodeficiency in ANCA Associated Vasculitis (ACQUIVAS)

Systemic Vasculitis
Queen Margaret University
NHS Lothian; Multiple Sclerosis Society UK

Completed

Walking With FES or AFO in People With MS With Foot Drop

Multiple Sclerosis | Foot Drop

United Kingdom
Queen Mary University of London
AstraZeneca; Cancer Research UK

Terminated

A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer (ZEBRA)

Metastatic Clear Cell Renal Carcinoma

United Kingdom
Alimentary Health Ltd
Whately-Smith Ltd, King's Langley,UK

Completed

Study in Patients With Mild to Moderate Psoriasis (AH-PSR-01)

Psoriasis

Ireland
University Hospital Birmingham NHS Foundation Trust
Pancreatic Cancer UK

Recruiting

The Development of a Metabolomic Test to Diagnose and Quantify Pancreatic Exocrine Insufficiency (The DETECTION Study) (DETECTION)

Pancreatic Exocrine Insufficiency

United Kingdom
The Leeds Teaching Hospitals NHS Trust
Cancer Research UK

Recruiting

Experiences and Perceptions of Colonoscopy and New Technologies

Bowel Cancer | Colonoscopy

United Kingdom

Clinical Trials Sponsored by Innovate UK

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations